XBIO Relative Valuation
XBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XBIO is overvalued; if below, it's undervalued.
Historical Valuation
Xenetic Biosciences Inc (XBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.92. The fair price of Xenetic Biosciences Inc (XBIO) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.44
Fair
-0.85
PE
1Y
3Y
5Y
Trailing
Forward
-0.26
EV/EBITDA
Xenetic Biosciences Inc. (XBIO) has a current EV/EBITDA of -0.26. The 5-year average EV/EBITDA is 0.04. The thresholds are as follows: Strongly Undervalued below -2.08, Undervalued between -2.08 and -1.02, Fairly Valued between 1.10 and -1.02, Overvalued between 1.10 and 2.16, and Strongly Overvalued above 2.16. The current Forward EV/EBITDA of -0.26 falls within the Historic Trend Line -Fairly Valued range.
-0.26
EV/EBIT
Xenetic Biosciences Inc. (XBIO) has a current EV/EBIT of -0.26. The 5-year average EV/EBIT is 0.04. The thresholds are as follows: Strongly Undervalued below -2.08, Undervalued between -2.08 and -1.02, Fairly Valued between 1.10 and -1.02, Overvalued between 1.10 and 2.16, and Strongly Overvalued above 2.16. The current Forward EV/EBIT of -0.26 falls within the Historic Trend Line -Fairly Valued range.
1.90
PS
Xenetic Biosciences Inc. (XBIO) has a current PS of 1.90. The 5-year average PS is 8.63. The thresholds are as follows: Strongly Undervalued below -10.39, Undervalued between -10.39 and -0.88, Fairly Valued between 18.14 and -0.88, Overvalued between 18.14 and 27.65, and Strongly Overvalued above 27.65. The current Forward PS of 1.90 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Xenetic Biosciences Inc. (XBIO) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Xenetic Biosciences Inc. (XBIO) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.25. The thresholds are as follows: Strongly Undervalued below -1.40, Undervalued between -1.40 and -0.82, Fairly Valued between 0.33 and -0.82, Overvalued between 0.33 and 0.91, and Strongly Overvalued above 0.91. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Xenetic Biosciences Inc (XBIO) has a current Price-to-Book (P/B) ratio of 0.94. Compared to its 3-year average P/B ratio of 0.75 , the current P/B ratio is approximately 26.44% higher. Relative to its 5-year average P/B ratio of 0.95, the current P/B ratio is about -0.19% higher. Xenetic Biosciences Inc (XBIO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -61.82%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -51.06% , the current FCF yield is about -100.00% lower.
0.99
P/B
Median3y
0.75
Median5y
0.95
-49.02
FCF Yield
Median3y
-61.82
Median5y
-51.06
Competitors Valuation Multiple
The average P/S ratio for XBIO's competitors is , providing a benchmark for relative valuation. Xenetic Biosciences Inc Corp (XBIO) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 67.19%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of XBIO decreased by 36.34% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 614.24K to 1.03M.
The secondary factor is the Margin Expansion, contributed -30.14%to the performance.
Overall, the performance of XBIO in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Xenetic Biosciences Inc (XBIO) currently overvalued or undervalued?
What is Xenetic Biosciences Inc (XBIO) fair value?
How does XBIO's valuation metrics compare to the industry average?
What is the current P/B ratio for Xenetic Biosciences Inc (XBIO) as of Dec 05 2025?
What is the current FCF Yield for Xenetic Biosciences Inc (XBIO) as of Dec 05 2025?
What is the current Forward P/E ratio for Xenetic Biosciences Inc (XBIO) as of Dec 05 2025?